Category: News

  Register now for the 2025 Summit for Cancer Immunotherapy this April in Toronto. With engaging panels, plenaries, keynote speakers, and networking events, the Summit4CI is an incredible opportunity to connect with colleagues from across research, academia, clinical practice, patient advocacy, government, and industry.   Visit the Summit4CI Conference section on our Summit4CI website for… Read more »

  1) What is the project you are working on in partnership with BioCanRx? What is your end goal with this project?   As a previous BioCanRx-funded Core facility as well as a funded network investigator, me and my team at OHRI’s BMC are currently working on a number of manufacturing projects and training initiatives…. Read more »

  Our In Their Words feature highlights our researchers and the work they do to improve cancer immunotherapy and work towards making all cancers curable diseases. Today, we hear from Megan Levings, who is working with the BC Children’s Hospital Research Institute.   1) What is the project you are working on in partnership with… Read more »

  Project: GO-TILT – Getting Better Outcomes with Tumour Infiltrating Lymphocyte Therapy Principal Investigators: Manoj Lalu, Dean Fergusson   What is the project you are working on in partnership with BioCanRx? What is your end goal with this project?   Our new research project is called Getting Better Outcomes with Tumour Infiltrating Lymphocyte Therapy (GO-TILT)…. Read more »

  We spoke to some of our researchers about their projects, their goals, and their hopes for Canadian cancer immunotherapy. Today, we hear from Jean-Simon Diallo.   What is the project you are working on in partnership with BioCanRx? What is your end goal with this project?   We are working in collaboration with Virica… Read more »

Expanded funding for existing BioCanRx projects By: Teffer Adjemian   Along with our partners, BioCanRx is pleased to announce our investment of a total of $4,579,988 funding seven continuing projects: five Enabling Studies, one Clinical Trial, and one Clinical, Social & Economic Impact project.   Bringing a product from the lab to the patient requires… Read more »

We are proud to present the BioCanRx 2023-24 Annual Report. While this year held uncertainties and more than a few questions, we continued to build on our strong foundation, completing research projects, collaborating with our network, and training the next generation of cancer immunotherapy researchers. This year also saw persistent growth in our commitment to… Read more »

    In this month’s FutureEconomy BioCanRx President and CEO Stéphanie Michaud discusses the opportunties and benefits to our economy and to the well being of Canadians made possible through investment in translational research and calls for greater and more sustained investment across Canada’s life sciences ecosystem.   https://thefutureeconomy.ca/op-eds/bridging-canadas-biotherapeutic-gap-a-call-for-strategic-investment-in-translational-research/  

  Building support for translational research through lessons learned By Vanessa Nelson   In early 2020, as Covid-19 began to spread widely, Canadian researchers and clinicians identified the need for new approaches, processes, and advisory and approval systems that could support innovative and novel responses to what was quickly becoming a health care emergency. Not… Read more »

By Heather Blumentha   Back in 2018, BioCanRx Scientific Director John Bell admitted that, in the beginning, he didn’t really appreciate the full potential of engaging patients. However, observing the interactions of patients and research trainees at BioCanRx’s annual scientific meeting convinced him of just how important that engagement is.   “I was hopeful that… Read more »